Literature DB >> 27846462

From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?

Ilja M Blok1, Annelieke C M J van Riel1, Arie P J van Dijk2, Barbara J M Mulder1, Berto J Bouma3.   

Abstract

Entities:  

Keywords:  Bosentan; Congenital heart disease; Macitentan; Pulmonary arterial hypertension

Mesh：

Substances：

Year:  2016        PMID： 27846462     DOI： 10.1016/j.ijcard.2016.11.211

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  13 in total

1.  MitoKATP channels promote the proliferation of hypoxic human pulmonary artery smooth muscle cells via the ROS/HIF/miR-210/ISCU signaling pathway.

Authors:  Hongling Hu; Yu Ding; Yang Wang; Shuang Geng; Jue Liu; Jinrong He; Yang Lu; Xueying Li; Mingli Yuan; Shan Zhu; Su Zhao
Journal:  Exp Ther Med       Date:  2017-10-17       Impact factor: 2.447

2.  Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension.

Authors:  Sabrina Schweintzger; Martin Koestenberger; Axel Schlagenhauf; Gernot Grangl; Ante Burmas; Stefan Kurath-Koller; Mirjam Pocivalnik; Hannes Sallmon; Daniela Baumgartner; Georg Hansmann; Andreas Gamillscheg
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

3.  Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension.

Authors:  Marzieh Nosrati; Nikinaz Ashrafi Shahmirzadi; Monireh Afzali; Pardis Zaboli; Hasti Rouhani; Haleh Hamedifar; Mirhamed Hajimiri
Journal:  J Family Med Prim Care       Date:  2020-07-30

4.  Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?

Authors:  M C J van Thor; L Ten Klooster; R J Snijder; J C Kelder; J J Mager; M C Post
Journal:  Lung       Date:  2019-10-03       Impact factor: 2.584

Review 5.  Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management.

Authors:  Michail Papamichalis; Andrew Xanthopoulos; Panagiotis Papamichalis; John Skoularigis; Filippos Triposkiadis
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

Review 6.  The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease.

Authors:  Alexandra C van Dissel; Barbara J M Mulder; Berto J Bouma
Journal:  J Clin Med       Date:  2017-03-30       Impact factor: 4.241

Review 7.  Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?

Authors:  Michele Correale; Armando Ferraretti; Ilenia Monaco; Davide Grazioli; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Vasc Health Risk Manag       Date:  2018-10-04

8.  Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update.

Authors:  Alexandra K Wong; Richard N Channick
Journal:  Drug Healthc Patient Saf       Date:  2019-09-03

9.  Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review.

Authors:  Daniel L Varela; Mohamed Teleb; Wael El-Mallah
Journal:  Open Heart       Date:  2018-01-09

10.  Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease.

Authors:  R Condliffe; P Clift; K Dimopoulos; R M R Tulloh
Journal:  Pulm Circ       Date:  2018-07-23       Impact factor: 3.017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.